The successful launch of Falcon Heavy prompts a roadmap for radioresistant astronauts

February 22, 2018

This massively-collaborative paper proposes the roadmap for making humans more resistant to radiation and multiple other forms of stress- and age- associated damage. For the first time the group presented the Hallmarks of Radioresistance.

"The cost of one productive life year (PLY) for humans in space is likely to be much higher than on Earth and efforts should be made to maximize PLYs of the colonists. If we cannot dramatically change healthcare and shift focus toward prevention, reinforcement and on Earth, it does not mean we should not try to allow the brave pioneers to withstand the harsh environment and enhance performance. High-LET radiation is among the first challenges that needs to be addressed and productive longevity will likely be a side effect of increased radioresistance. Nations worldwide should consider putting aside the ideological differences that lead to segregation and slowdown in science and unite around achieving increased longevity and health of the space travellers", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

Substantial efforts are being made around the world to colonize the moon and Mars, mine the asteroids and explore deep space. These efforts are primarily focused on technological capabilities including better and more efficient rockets and sustainable habitats. However, the strategies to tackle space radiation have been largely overlooked. The main components of space radiation are solar particle events (SPE), geomagnetically trapped radiation and galactic cosmic radiation (GCR). It has been estimated that a return trip to Mars could subject astronauts to radiation doses of 660 mSv, which alone represents more than half of the total NASA astronaut career limit of 800-1200 mSv. Launching humans into space is going to be very expensive and arranging for proper medical care is going to be difficult at first and new strategies are needed to increase stress resistance and reduce the health-related uncertainties that can be detrimental to the future of space colonization.

"Elon Musk demonstrated that it is possible to set very ambitious goals in the private sector and successfully achieve them. At Insilico Medicine we set very ambitious goals and our Falcon Heavy is the fully-integrated end-to-end drug discovery pipeline utilizing the next-generation artificial intelligence and it will launch this Summer. And while our immediate goal is to transform the pharmaceutical industry in the most credible way, the same AI pipeline can be applied to discovery and development of new therapeutic strategies including geroprotectors, senoremediators and radioprotectors", said Ivan Ozerov, PhD, the director of target discovery at Insilico Medicine.

The strategies for achieving the increased radioresistance and longevity will be presented at the 5th Annual Aging Research for Drug Discovery Forum and the 2nd Annual Artificial Intelligence and Blockchain Technologies for Healthcare Forum in Basel as part of the Basel Life Congress, September 11-14, 2018.

Insilico Medicine is regularly publishing many "firsts" and proofs of concept in the application of deep learning to drug discovery and biomarker development. It was the first to apply the deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. The latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at JHU in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products. It also provides a range of consumer-facing applications including Young.AI and Aging.AI.

The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Website:

InSilico Medicine, Inc.

Related Radiation Articles from Brightsurf:

Sheer protection from electromagnetic radiation
A printable ink that is both conductive and transparent can also block radio waves.

What membrane can do in dealing with radiation
USTC recently found that polymethylmethacrylate (PMMA) and polyvinyl chloride (PVC) can release acidic substance under γ radiation, whose amount is proportional to the radiation intensity.

First measurements of radiation levels on the moon
In the current issue (25 September) of the prestigious journal Science Advances, Chinese and German scientists report for the first time on time-resolved measurements of the radiation on the moon.

New biomaterial could shield against harmful radiation
Northwestern University researchers have synthesized a new form of melanin enriched with selenium.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
Oncotarget Volume 11, Issue 4: In this study, locally advanced head and neck cancer patients undergoing definitive chemoradiation were randomly allocated to weekly cisplatin - radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.

Breaking up amino acids with radiation
A new experimental and theoretical study published in EPJ D has shown how the ions formed when electrons collide with one amino acid, glutamine, differ according to the energy of the colliding electrons.

Radiation breaks connections in the brain
One of the potentially life-altering side effects that patients experience after cranial radiotherapy for brain cancer is cognitive impairment.

Fragmenting ions and radiation sensitizers
The anti-cancer drug 5-fluorouracil (5FU) acts as a radiosensitizer: it is rapidly taken up into the DNA of cancer cells, making the cells more sensitive to radiotherapy.

'Seeing the light' behind radiation therapy
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime.

Read More: Radiation News and Radiation Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to